SBIR/STTR Research Award

Clinical Human Cell Production System for Broad Use

Award identifier 2cdc6d143e1b463b2a6aa75d67829445b4586060cf38b4064488990997abfe96Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$798,266

Program and phase

SBIR · Phase II

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Aastrom Biosciences, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

The therapeutic potential of patient-specific cultured cells continues to rapidly grow for a range of medical needs, such as regenerative repair of damaged tissue, cancer, and infectious diseases. As a result, the motivation to commercialize patient-specific "cell products" is increasing rapidly as well. A large unmet need exists for the development of reliable clinical and commercial ceil manufacturing capability for these cell products in compliance with increasingly strict regulatory guidelines and where the production economics are more favorable so that the benefits of cell therapy can be more widely enjoyed. In Phase I, a prototype system was defined and constructed that incorporated Aastrom's single-pass perfusion technology for highly effective primary human cell production along with a sterile, closed fluid path and a robotic instrument to perform operational steps (e.g. priming, inoculation, harvest). The approach provides general flexibility to enable researchers to develop and optimize a wide range of production processes, over a variety of cell types, as well.as cost-effective scale-up to clinical and commercial cell manufacturing. A non-adherent T-Cell process and an adherent stromal cell process were successfully demonstrated with the prototype. In Phase II, process control methods and additional automation technology will be developed, a modular configuration strategy will be defined, system components developed to enable cell manufacturing over a wide range of scale, and a test configuration constructed and tested to validate the design. Successful completion of Phase II will provide the technology and results necessary to initiate a commercialization phase to include both the use of the modular system as component technology to support commercialization of Aastrom's proprietary Tissue Repair Cell (TRC) products as well as the direct commercialization of the system for use by other institutions planning to commercialize therapeutic cell products.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.